stockrow
Friday 6 November 2026
Export CAI’s income statement to Excel — free account
Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- Revenue
- +27.0%
- EPS
- −40.3%
- Free cash flow
- −140.2%
- Total debt
- +4.46%
Quarter to September 2026, against a year earlier
25.15
0.88
−3.38%
Follow CAI
Alert me
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 | 9.38 |
Altman Z-Score |
— | — | 3.55 |
Altman Z″-Score (non-manufacturers) |
— | (28.44) | (0.93) |
P/FCF ratio |
0.00 | 0.00 | 113.82 |
Beneish M-Score |
— | — | (2.71) |
P/Operating CF |
(31.83) | (31.83) | 170.04 |
P/B ratio |
0.00 | 0.00 | 13.19 |
Price to Tangible BV |
0.00 | 0.00 | 13.65 |
EV/Sales |
0.00 | 0.00 | 8.86 |
EV/EBITDA |
0.00 | 0.00 | 89.36 |
EV/Operating CF |
(4.73) | (4.73) | 86.50 |
EV/FCF |
(4.55) | (4.55) | 107.53 |
Quick Ratio |
— | 0.94 | 7.17 |
Current Ratio |
— | 1.30 | 7.85 |
Net Debt/EBITDA |
0.00 | (1.55) | (5.23) |
Debt/Assets |
0.00% | 110.41% | 33.67% |
Debt/Equity |
0.00 | (0.15) | 0.66 |
Asset Turnover |
0.00 | 2.40 | 1.11 |
Operating CF/Net income |
0.60 | 0.65 | (0.15) |
Capex/Depreciation |
(0.41) | (0.15) | (0.46) |
Interest Coverage |
(10.11) | (5.14) | 0.79 |
| 0.00% | 0.00% | 55.99% | |
| 0.00% | (220.09%) | (73.22%) | |
ROIC |
0.00% | 0.00% | 18.05% |
Return on Tangible Assets |
0.00% | (320.22%) | (57.61%) |
Average Days of Receivables |
0.00 | 78.13 | 50.41 |
Research and Development Expense of Revenue |
38.18% | 27.63% | 12.51% |
Selling, General and Administrative Expense of Revenue |
95.38% | 78.10% | 48.33% |
Intangible Assets out of Total Assets |
0.00 | 0.06 | 0.02 |
Share Based Compensation of Revenue |
4.98% | 4.52% | 8.62% |
Graham Net Nets |
(2.63) | (2.63) | 0.06 |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(62.39%) | (62.39%) | (41.36%) |
Free Cash Flow Yield |
(28.84%) | (28.84%) | 0.88% |
Revenue per Share |
8.76 | 11.61 | 4.86 |
Operating CF per Share |
(7.90) | (6.91) | 0.50 |
Capex per Share |
(0.64) | (0.24) | (0.10) |
Free Cash Flow per Share |
(8.54) | (7.15) | 0.40 |
Cash per Share |
0.00 | 1.91 | 4.79 |
Shareholders Equity per Share |
0.00 | (70.40) | 3.45 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | (70.40) | 3.45 |
Free Cash Flow |
(298.42) | (253.64) | 66.90 |
Working Capital |
— | 50.31 | 870.66 |
Capital Expenditures |
(22.32) | (8.44) | (16.26) |
Net Current Asset Value |
0.00 | (2,626.84) | 449.44 |
EV/EBIT |
0.00 | 0.00 | 159.45 |
Capex to Sales |
0.07 | 0.02 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 168.78 |
| Other line items | |||
Depreciation/Fixed assets |
0.00 | 0.83 | 0.56 |
Cash ROIC |
0.00% | 12.36% | 3.81% |
Accounts Receivable Turnover |
0.00 | 0.00 | 8.10 |
Accounts Payable Turnover |
0.00 | 0.00 | 8.15 |
Inventory Turnover |
0.00 | 0.00 | 5.29 |
Average Days of Payables |
0.00 | 43.45 | 52.44 |
Days of Inventory on Hand |
0.00 | 61.86 | 85.11 |
Average Receivables |
— | — | 100.19 |
Average Payables |
— | — | 33.50 |
Average Inventory |
— | — | 51.60 |
Average Assets |
— | 171.87 | 734.70 |
Average Common Equity |
— | — | (960.77) |
Columns are period end dates · fundamentals updated 4 Nov 2026